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Background: Recently, a growing number of novel genetic defects underlying primary 
immunodeficiencies (PIDs) have been identified, increasing the number of PID up to 
more than 250 well-defined forms. Next-generation sequencing (NGS) technologies and 
proper filtering strategies greatly contributed to this rapid evolution, providing the possi-
bility to rapidly and simultaneously analyze large numbers of genes or the whole exome.
Objective: To evaluate the role of targeted NGS and whole exome sequencing (WES) 
in the diagnosis of a case series, characterized by complex or atypical clinical features 
suggesting a PID, difficult to diagnose using the current diagnostic procedures.
Methods: We retrospectively analyzed genetic variants identified through targeted NGS 
or WES in 45 patients with complex PID of unknown etiology.
results: Forty-seven variants were identified using targeted NGS, while 5 were iden-
tified using WES. Newly identified genetic variants were classified into four groups: (I) 
variations associated with a well-defined PID, (II) variations associated with atypical 
features of a well-defined PID, (III) functionally relevant variations potentially involved in 
the immunological features, and (IV) non-diagnostic genotype, in whom the link with 
phenotype is missing. We reached a conclusive genetic diagnosis in 7/45 patients 
(~16%). Among them, four patients presented with a typical well-defined PID. In the 
remaining three cases, mutations were associated with unexpected clinical features, 
expanding the phenotypic spectrum of typical PIDs. In addition, we identified 31 variants 
in 10 patients with complex phenotype, individually not causative per se of the disorder.
conclusion: NGS technologies represent a cost-effective and rapid first-line genetic 
approach for the evaluation of complex PIDs. WES, despite a moderate higher cost 
Abbreviations: ACMG, American College of Medical Genetics; ALPS, autoimmune lymphoproliferative syndrome; CMC, 
chronic mucocutaneous candidiasis; MYD88, myeloid differentiation factor 88; NGS, next-generation sequencing; PIDs, 
primary immunodeficiencies; SNVs, single nucleotide variants; TLR, toll-like receptor; T-NGS, targeted next-generation 
sequencing; WES, whole exome sequencing; WGS, whole genome sequencing.
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inTrODUcTiOn
Primary immunodeficiencies (PIDs) represent a heterogeneous 
group of monogenic disorders including more than 250 geneti-
cally defined diseases, mostly identified in recent years (1–3). 
A significant contribution to this rapid evolution is due to the 
integration of functional studies with the use of next-generation 
sequencing (NGS) technologies. The specific objective of this 
strategy is the identification of putative pathogenic alterations in 
known or novel genes implicated in well-defined biological path-
ways (4–7). However, despite the breadth of current knowledge, 
the diagnostic approach used for the identification of genetic 
causes underlying PID appears inefficient and time-consuming 
as the majority of PID cases remain without a diagnosis even 
after extensive clinical and genetic investigations (8). Moreover, 
even in a single PID gene mutation, a genotype–phenotype cor-
relation is often missing, because various clinical phenotypes 
may be related to the same genetic defect and vice versa (9, 10). 
Nevertheless, early diagnosis in severe forms of PIDs is crucial to 
establish a proper treatment and improve the overall outcome (11, 
12). In the traditional approach to PIDs, the molecular diagnosis 
has long been based on the sequencing of multiple genes by the 
Sanger method, a time-consuming strategy, which often results in 
delayed diagnosis (13).
Next-generation sequencing technology has become a valu-
able first-line diagnostic tool for the timely diagnosis of genetic 
disorders, in particular for complex clinical presentation (14). 
NGS allows rapid, cost-efficient, accurate, and high-throughput 
sequencing of millions of DNA fragments in a reasonably short 
time. Whole exome sequencing (WES) is limited to the cod-
ing regions and splice junctions of the genome, which despite 
accounting for only ~2% of the genome, contain about 85% of 
genetic alterations known as responsible for human diseases (15).
In PIDs, a targeted sequencing approach, restricted only to 
specific genes or to specific regions of interest is a reasonable 
possibility to identify putative pathogenic variants that explain 
a specific disorder, their related altered biological pathway, and 
the array of genes that are transcribed. This can be the first-line 
alternative as it involves a smaller dataset than WES or whole 
genome sequencing (WGS) and is easier for the management of 
the datasets (16–18). However, as the spectrum of distinct clinical 
entities and the presenting phenotypes are expanding because of 
the discovery of novel genes and of the identification of wider 
clinical phenotypes, the differential diagnosis and subsequent 
diagnostic targets must improve in parallel. This perspective 
makes the whole exome or genome sequencing strategy attractive 
options for the diagnosis of patients with PID (19).
Here, we report on a case series of 45 complex or atypical 
clinical phenotypes that were suggestive of PID, but difficult 
to diagnose in a timely manner using the current diagnostic 
procedures. Our aim was to use current NGS technology to help 
diagnose PID in this cohort of patients. We used T-NGS and WES 
in 27 and 18 patients, respectively.
MaTerials anD MeThODs
Patients
We have studied 45 patients with a clinical history highly 
suggestive of a primary immunological defect, that were 
 heterogeneous for ethnic origin, age, and sex. The patients were 
selected on the basis of clinical features and abnormal immune 
parameters (20). The clinical criteria included one or more of 
the following features: opportunistic infections, granuloma, 
chronic mucocutaneous candidiasis (CMC), intractable diar-
rhea, bronchiectasis, and severe autoimmunity. These symptoms 
were associated, in some patients, with non-immunological 
features. In six patients, a positive family history for a similar 
phenotype was observed. Clinical criteria were considered 
if associated with one or more of the following quantitative 
and/or qualitative immunological abnormalities: abnormal 
lymphocyte subsets (absolute count <2 SD of normal values 
according to ESID criteria); proliferative response to mitogens 
<10% of the levels measured in the control subject; absent/poor 
specific antibody response; hypogammaglobulinemia; elevated 
IgE levels (>2000 kU/l); severe impairment of cytolytic activ-
ity; and alteration of class switch recombination (CSR) with or 
without hyper-IgM. PID patients, selected on the basis of the 
above specified criteria, were subsequently grouped on the basis 
of NGS results, functional alterations, and consistency between 
genotype, phenotype, and immune assays.
The study was approved by the Institutional Ethical 
Committee “Carlo Romano” of Federico II University and by 
Ethical Committee of Spedali civili (Brescia) and conducted after 
informed consent was obtained.
Dna extraction and sequence capture 
array Design
Genomic DNA was isolated from peripheral blood lymphocytes 
with QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). 
Quantity and quality were determined through the Epoch 
Microplate Spectrophotometer (BioTech Instruments, Winooski, 
VT, USA). A panel of 571 genes, including 68 genes known or 
predicted to be related to PIDs and/or immune regulation, was 
compared to targeted, is emerging as a valuable tool to reach in a timely manner, a 
PID diagnosis with a considerable potential to draw genotype–phenotype correlation. 
Nevertheless, a large fraction of patients still remains without a conclusive diagnosis. In 
these patients, the sum of non-diagnostic variants might be proven informative in future 
studies with larger cohorts of patients.
Keywords: primary immunodeficiencies, genetic diagnosis, targeted next-generation sequencing, whole exome 
sequencing, genotype–phenotype correlation
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sequenced (Table S1 in Supplementary Material). Basically, broad 
searches in literature, PubMed queries and expert suggestions 
defined the gene panel. We used BioMart (Ontario Institute for 
Cancer Research/European Bioinformatics Institute) to retrieve 
the coordinates of all exons for the specified genes from Ensembl. 
Coordinates were based on the current human reference genome 
(hGRC37, hg19).
next-generation sequencing and 
Bioinformatics analysis
Samples were sequenced using either a targeted panel of 571 
(TaGSCAN v2.0) or WES for enrichment. Briefly, TaGSCAN 
samples were prepared for sequencing using Illumina’s TruSight 
Inherited Disease panel according to manufacturer’s protocols 
(Illumina, San Diego, CA, USA). Samples were sequenced to 
at least 2.5  GB on an Illumina MiSeq with TruSeq MiSeq V3 
reagents, yielding paired 250 nucleotide reads. Samples were 
prepared for exome sequencing using the TruSeq HT library 
preparation kit (Illumina; San Diego, CA, USA) followed by 
exome enrichment using the xGen Exome Research Panel V1.0 
(Integrated DNA Technologies; Coralville, IA, USA) according to 
manufacturers’ protocols. Paired-end 2 bp × 125 bp sequencing 
was completed on an Illumina HiSeq 2500 instrument in high 
output mode using V4 Chemistry. Samples were sequenced to at 
least 7 GB of data resulting in a minimum target coverage of 50×. 
For all samples, sequence was assembled, aligned to reference 
gene sequences based on human genome build GRCh37/UCSC 
hg19, and analyzed using custom-developed software, RUNES 
and VIKING (21).
Alignment, variant calling, and analysis were performed, as 
described previously (21). In detail, variants were filtered by fre-
quency and variant category (22). Variant analysis was confined 
to coding and splice variants with a minor allele frequency (MAF) 
of 1% or less in the CMH internal database, in the Exome Variant 
Server (EVS)1 and Exome Aggregation Consortium (ExAC).2 
Other tools used to restrict NGS analysis to a set of gene-asso-
ciated regions relevant to clinical presentations, was symptom- 
and sign-assisted genome analysis (SSAGA), which mapped the 
clinical features in ill neonates and children to disease genes, and 
Phenomizer databases (21, 23). Sorting Intolerant From Tolerant 
(SIFT) and Polymorphism Phenotyping v2 (PolyPhen2) have 
been used to provide information on the impact of the variants.
Functional assays and sanger Validation
Functional assays were performed to prove the impact of vari-
ants identified by NGS. Functional studies included lymphocyte 
proliferation assays performed through [3H]thymidine incor-
poration assay, natural killer cell-mediated lysis of target cells 
and lymphocyte apoptosis induced by FAS death receptor cross-
linking, evaluated through flow cytometry, cytokines production 
after toll-like receptors (TLR) stimulation, evaluated through 
real-time PCR. Furthermore, protein expression was evaluated 
through western blot analysis and standard procedures. After 
1 http://evs.gs.washington.edu/EVS. 
2 http://exac.broadinstitute.org/. 
identification of genetic variants that were predicted to be dam-
aging, along with consistent genotype–phenotype correlation, 
mutations were validated by Sanger sequencing using standard 
protocols. In 9 patients, we detected 11 variants that were con-
firmed by Sanger sequencing.
additional Phenotype-Based Variant 
Filtering criteria
In order to identify potential causal mutations, annotated vari-
ants were further prioritized based on the following criteria:
 – homozygous or heterozygous variants already reported that 
were related to any immunological clinical phenotype were 
selected to be further investigated by functional studies and 
validated by Sanger method;
 – variants in genes implicated in a molecular pathway related to 
the phenotype were considered if associated with any func-
tional alteration, which was even partially consistent, with the 
clinical phenotype;
 – all the genetic variants of genes that were probably unrelated 
to the molecular pathway suspected to be involved in the 
pathogenesis of the disease were excluded from the functional 
studies, but reported in an ad hoc repository.
resUlTs
ngs of 45 Patients
Genomic DNA from 27 patients was enriched for all exons from 
571 genes, including genes involved in immunological pathways, 
while DNA from 18 patients was enriched for all nucleotides of 
the exome. DNA from six patients, analyzed with TaGSCAN, was 
subsequently sequenced for the entire exome and the bioinfor-
matic analysis of data results is currently ongoing. For TaGSCAN, 
98.9% of base pairs targeted had at least 10× coverage. Mean depth 
of coverage was 580×. WES covered 97.05% of exonic regions 
at 10× or greater on average. The overall analytic sensitivity for 
single nucleotide variants (SNVs) was 98.7%.
The results of NGS exon sequencing are shown in Tables 1–4. 
After bioinformatics analysis and filtering, the potential causative 
nucleotide changes needed to be further evaluated in each indi-
vidual patient (Table 5). All of these variants were SNVs or small 
indel variants, with no other alteration such as large deletions or 
insertions identified.
A satisfying molecular diagnosis of PID was achieved in 7 
of the 45 patients (16%), including 3 patients with an atypical 
presentation. Three causative variations were identified through 
T-NGS, while five through WES. On the basis of the genetic 
findings and of the clinical phenotypes, patients were divided 
in four groups. Group 1 included subjects with a diagnostic 
genotype that was previously associated with an immunologi-
cal and/or clinical phenotype already reported for that genetic 
disease. Group 2 included subjects with a diagnostic genotype 
associated with novel or atypical clinical features of a genetic 
disease. In the group 3, NGS revealed multiple genetic variants 
that were consistent only with some features of the clinical and 
immunological phenotype. Group 4 included patients with a 
complex unclassified disorder that was associated with multiple 
TaBle 3 | genetic variants potentially involved in the immunological features.
Patient ngs 
method
gene Mutation Protein Prediction score Zygosity Major clinical features
siFT PolyPhen2
8 T-NGS UNC13D c.335G>C p.Cys112Ser 0.38 0.832 Het Acute lymphoblastic leukemia treated with 
allogeneic HSCT, ethmoiditis, recurrent 
lymphadenopathy, autoimmune cytopenia, arthritis, 
hypogammaglobulinemia, hyper-IgM, IgA deficiency
CASP10 c.683C>T p.Pro228Leu 0.07 0.071 Het
9 T-NGS CASP10 c.1202_1208del p.Cys401LeufsTer15 – – Het Alopecia universalis, hyperthyrotropinemia, type 
I diabetes mellitus, dental enamel hypoplasia, 
developmental delay, short stature, candidiasis, 
hepatomegaly, multiple skeletal abnormalities, 
myopia, dysmorphic features, microcephaly, 
abnormal FAS-induced apoptosis. Hyper IgE
10 T-NGS DOCK8 c.1907A>G p.Lys636Arg 0.4 0.057 Het Inflammatory bowel disease, short stature, 
aspergillosis, EBV infection, low CD4+ lymphocyte 
subset, increased CD4 CD8 double-negative T 
cells, normal antibody response
TLR3 c.2672A>G p.His891Arg 0.01 0.309
11 T-NGS ADA c.377C>A p.Pro126Gln 0 0.999 Het T−B+NK− SCID treated with bone marrow 
transplantation, P. jirovecii pneumonia, recurrent 
otitis, absent ossicular bone with hypoacusia of the 
right ear, mild brain, and cerebellar atrophy, speech 
delay, scoliosis
c.1047A>G p.K349= – –
ERCC6 c.3262A>G p.Ser1088Gly 0.48 0.001
c.2697G>A p.T899= – –
12 T-NGS AP3B1 c.787G>T p.Gly263Cys 0.05 0.932 Het Interstitial lung disease CMV infection, esophageal 
candidiasis, strabismus, abnormal expression of 
perforin in NK cells, reduction of CD4+ cells with 
increase of CD19+, normal proliferative response to 
mitogens, normal antibody response
PRF1 c.695G>A p.Arg232His 0.02 0.991
c.272C>T p.Ala91Val 0.01 0.808
ADAMTS13 c.2701G>T p.Ala901Ser 0.61 0.049
In this group of patients, T-NGS allowed to identify multiple variants not causative of a specific PID, but with a possible impact on the disease.
TaBle 2 | genetic variants associated with novel features of PiD.
Patient ngs 
method
gene Mutation Protein Prediction score Zygosity inheritance clinical and immunological phenotype
siFT PolyPhen2
005 T-NGS MYD88 c.192_194del p.Glu66del – – Hom AR Chronic yersiniosis and terminal ileitis, recurrent 
severe cutaneous granulomatous abscesses, 
hyper IgE, hypereosinophilia, neutropenia
006 WES PLDN c.232C>T p.Q78X – – Hom AR Partial oculocutaneous albinism, 
nystagmus, recurrent cutaneous infections, 
thrombocytopenia, leukopenia, NK deficiency
007 WES DOCK8/ 
CLEC7A
c.3193delA p.Ser1065Ala – – Hom/Hom AR Intractable diarrhea, eczema, malignancy, food 
allergies, hyper IgE, lymphopeniaX17/p.Tyr238X
MYD88 variant was identified through T-NGS in a patient with atypical features of MyD88 deficiency, presenting with chronic yersiniosis. PLDN variant was identified through WES 
in a patient with incomplete features of Hermansky–Pudlak type II syndrome and impairment of NK cytolytic activity. DOCK8/CLEC7A variants were identified for the first time in a 
patient with intractable diarrhea, malignancy, and features of Hyper IgE syndrome.
TaBle 1 | genetic variants associated with typical PiD.
Patient ngs method gene Mutation Protein Zygosity inheritance clinical and immunological phenotype
001 T-NGS CD40LG c.373C>T p.His125Tyr Hom XL Severe hypogammaglobulinemia with hyper-IgM, neutropenia, 
P. jirovecii pneumonia, CMV infection, intractable diarrhea
002 WES STAT1 c.847T>A p.Leu283Met Het AD Chronic mucocutaneous candidiasis, recurrent pneumonia, 
hypothyroidism, lymphopenia, poor vaccine response
003 WES BTK c.1105C>T p.Leu369Phe Hom XL Agammaglobulinemia
004 T-NGS JAK3 c.856C>T p.Gln286Ter Hom AR T−B+NK−SCID, chronic diarrhea, poor proliferative response to 
mitogens, IgA deficiency
CD40LG and JAK3 variants were identified with T-NGS and STAT1 and BTK variants identified with WES. These variations were found in patients with clinical phenotype of classic 
well-defined PIDs.
4
Gallo et al. Next-Generation Sequencing in Primary Immunodeficiencies
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 466
TaBle 4 | genetic variants not causative of PiD with undetermined impact on the disease.
Patient ngs 
method
gene Mutation Protein Prediction score Zygosity Major clinical features
siFT PolyPhen2
13 T-NGS CFTR c.2991G>C p.Leu997Phe 0.08 0.18 Het Late onset hypogammaglobulinemia, recurrent 
pneumonia, bronchiectasis, chronic sinusitis, cervical 
and mediastinal lymphadenopathy, recurrent abdominal 
pain, hepatomegaly with low grade steatosis, 
splenomegaly
14 T-NGS SYCE2 c.577G>A p.Val193Met 0.28 0 Het t(11;18)MLT1-AP12 gastric maltoma HP+, persistent 
oral candidiasis, sinusitis; lung cystis, chronic cough, 
recurrent fever, hypereosinophilia, recurrent itch, 
recurrent myofasciitis, hyper-IgM, altered somatic 
hypermutation, absent CD19+CD20− IgG+ (mature), low 
CD19+CD27+IgM+ (memory), absent CD19+CD27+IgM− 
(switched memory)
LYST c.10235G>A p.Arg3412His 0.02 0.997
15 T-NGS ATR c.5257A>G p.Ile1753Val 0.16 0.403 Het Severe aplastic anemia, hepatomegaly, Legionella 
sp. and Aspergillus recurrent pneumonia, metacarpal 
deforming alterations with bone demineralization, 
abnormal lymphocyte proliferation, dilated 
cardiomyopathy, early retinopathy
ARSA c.869G>A p.Arg290His 0.55 0.959 Het
CASP10 c.683C>T p.Pro228Leu 0.07 0.071 Het
IKBIKG c.1165C>T p.Pro389Ser 0.29 0.041 Het
MEFV c.460T>C p.Ser154Pro 0.04 0.001 Het
SP110 c.1114C>T p.Arg372Ter – – Het
UNC13D c.335G>C p.Cys112Ser 0.38 0.852 Het
16 T-NGS ATRX c.2247_2249del p.Ser750del – – Het Autoimmune adrenal insufficiency, autoimmune 
thyroiditis, lymphadenopathy, autoimmune 
thrombocytopenia, and neutropenia
c.2133_2135del p.Ser712del – – Hom
MYD88 c.10_28del p.Ala6ProfsTer39 – – Het
DOCK8 c.2920C>A p.His974Asn 0.34 0.001 Het
c.3016C>A p.His1006Asn 0.33 0.003 Het
c.3220C>A p.His1074Asn 0.33 0.003 Het
17 T-NGS TYK2 c.3488A>G p.Glu1163Gly 0.27 0.006 Het Hypogammaglobulinemia, familial IgA deficiency, hyper 
IgE, multiple bronchiectasis, candidiasis
18 T-NGS TLR3 c.634-10C>A – – – Het Familial IgA deficiency, multiple bronchiectasis, 
recurrent respiratory infections, low IgM levelsIntron
19 T-NGS CASP10 c.1094A>C p.Tyr365Ser 0 0.982 Het Mild hypogammaglobulinemia, undetectable CD16+ 
lymphocyte levels, pervasive developmental disorderERCC5 c.2375C>T p.Ala792Val 0 1 Het
GJC2 c.256G>A p.Val86Ile 0.13 0.825 Het
PEX26 c.728C>T p.Ala243Val – – Het
RAB23 c.536A>C p.Glu 179Ala – – Het
UBR1 c.3290C>T p.Thr1097Met – – Het
20 T-NGS CD3-ZETA c.301C>T p.Gln101Ter – – Het Hypogammaglobulinemia, recurrent pneumonia, 
transient alopecia, behavioral disorders, oropharyngeal 
candidiasis
OCRL c.2032A>G p.Ser678Gly 0 0.986 Hem
21 T-NGS PKHD c.5125C>T p.Leu1709Phe 0.15 1 Het Multi-organ failure and hypocalcemia during EBV 
infection, persistent EBV infection, kidney single cystic 
formation, hyper IgE, normal antibody response and 
proliferative response to mitogens, normal perforin 
intracytoplasmic expression, normal degranulation 
assay, reduced production of IFNγ
NPHP3 c.2864del p.Asp955ValfsTer2 – – Het
G6PC c.634A>G p.Ile212Val 0.88 0.01 Het
22 T-NGS RAB27 c.418C>G p.Gln140Glu 1 0.24 Het Recurrent fever, oral aphthous, diarrhea, laterocervical
LYST c.6482A>C p.Glu2161Ala 0.03 0.002 Het lymphadenopathy, hepatomegaly, increased level 
of amyloid protein, recurrent pneumonia, increased 
level of IgA, hyper IgE increased double-negative 
lymphocytes, normal functional Fas assay
In this fourth group, T-NGS led to identify multiple genotypic alterations in patients showing complex phenotypes, which could not fit into defined clinical syndromes. In this group, no 
genotype–phenotype relationship was possible. However, since these cases are extremely rare, these data should likewise be collected in a database for future studies pointing to 
the sum of alterations on the whole.
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genetic variants, each of them, individually, was not per  se 
causative of the disorder. However, regarding the variants of 
groups 3 and 4, it should be pointed out that, since parental 
cosegregation studies were not performed, the variants may 
not be truly disease-causing or disease-modifying alterations, 
especially if inherited together from an unaffected parent.
The first group included four subjects who have been identi-
fied for a genetic defect associated with a known well-established 
TaBle 5 | gene variants confirmed by sanger sequencing, functional assays and/or previous report.
gene Mutation sanger confirmation Functional assays reference
CD40LG c.373C>T Yes Absent expression of CD40L after stimulation (24)
BTK c.847T>A Yes NA (25)
STAT1 c.1105C>T Yes IFNα- and IFNγ-induced increased level of pSTAT1 (26)
JAK3 c.856C>T Yes Abnormal proliferative response to mitogens –
MYD88 c.192_194del Yes Reduced levels of IL-6, IL-1, CCL2, and CCL3 after TLR 
stimulation with LPS, IL-1, TNFα; rescue of IL-1β and LPS 
responsiveness after WT MYD88 gene transfection
(27, 28)
PLDN c.232C>T Yes Absent PLDN protein expression (29, 30)
DOCK8/CLEC7A c.3193delA Yes Low level of DOCK8 protein expression (31)
UNC13D c.335G>C NA NA (32)
CASP10 c.683C>T NA NA –
CASP10 c.1202_1208del Yes Abnormal Fas-induced apoptosis in PHA-activated T cells –
DOCK8 c.1907A>G NA – –
TLR3 c.2672A>G NA Normal INFγ production after TLR3 stimulation –
ADA c.377C>A NA Abnormal proliferative response to mitogens (33, 34)
ERCC6 c.3262A>G NA NA –
AP3B1 c.787G>T NA NA –
PRF1 c.695G>A Yes Reduced expression of perforin in NK cells (35)
ADAMTS13 c.2701G>T NA NA –
For each variant, the Sanger confirmation, the functional assays, and references for variants already published were reported.
NA, not applied.
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immunological and/or clinical phenotype of PID (Table  1). In 
detail, variants in CD40LG, BTK, STAT1 genes were already 
reported in literature as pathogenic (24–26). The JAK3 nonsense 
variant was predicted to result in nonsense-mediated decay 
resulting in no protein expression. This mutation, though not 
previously reported, was fully congruent with the classic JAK3–
SCID phenotype observed in multiple affected family members 
who shared the same genotype (proband and two siblings).
The second group included other three subjects in whom 
genetic variants were found as associated with novel phenotypic 
features, in previously characterized phenotypes (Table  2). 
Specifically in this group, patient 005 was found to carry a homozy-
gous mutation in MYD88 (c.192_194del; p.Glu66del), previously 
reported in several MYD88 deficiency affected families (27, 28). 
This patient was of a Rom ethnicity and had inherited the deletion 
from his unaffected consanguineous parents. But, early infant 
deaths due to severe infections were observed in the same family 
pedigree. Functionally, known mutations result in impairment of 
cytokine production after TLR stimulation (36, 37). Patients 006 
and 007 were found to carry homozygous deleterious mutations 
in PLDN and DOCK8/CLEC7A gene, respectively, whose pheno-
typic peculiarity has been described in detail (29, 31).
The third group of subjects included five patients who car-
ried multiple heterozygous variants affecting genes expressed 
in the hematopoietic system that were not consistent with a 
specific PID (Table 3). However, some of these patients might 
harbor a second mutation that was not identified by NGS or 
Sanger sequencing. In patient 008, we observed a heterozy-
gous, probably, pathogenic variant in UNC13D (c.335G>C 
p.Cys112Ser), and a heterozygous, most likely benign variant 
in CASP10 gene (c.683C>T p.Pro228Leu; exon 10 not cov-
ered). This patient had a clinical phenotype consistent with an 
autosomal dominant type  II ALPS (ALPS-II), associated with 
hypogammaglobulinemia and acute lymphoblastic leukemia. 
Even though the CASP10 variant alone in the in silico prediction 
programs, PolyPhen2 and SIFT, was predicted to be tolerated and 
was observed in 35 healthy individuals (ExAC), its significance 
in association with the second deleterious variant in UNC13D 
has never been described and could be potentially relevant. 
In fact, this UNC13D variant has been previously reported in 
association with heterozygous mutation of FAS and is considered 
a disease modifier for ALPS (32). In patient 009, we found by 
T-NGS a heterozygous frameshift variant in CASP10 causative 
of ALPS-II and categorized as likely pathogenic according to 
American College of Medical Genetics (ACMG) criteria (22). 
His immunological phenotype was characterized by very high 
IgE levels (>2000  IU). The functional analysis of Fas-induced 
apoptosis in PHA-activated T cells from the patient confirmed 
that the apoptotic pathway was impaired, since cell apoptosis 
upon triggering of Fas was impaired (92% survival; normal 
values: median 60%, 95th percentile 82%). His brother, who 
presented with similar manifestations, died early in life because 
of hemophagocytic lymphohistiocytosis. In addition, the patient 
009 also had additional clinical features, such as developmental 
delay, microcephaly, peculiar facial dysmorphism, and skeletal 
abnormalities, which could not be at moment demonstrated or 
excluded to be directly explained by the variant. In patient 010, 
we found two heterozygous variants of unknown significance 
in DOCK8 and TLR3 with good coverage of each gene and 
no second variant. The TLR3 variant had multiple lines of 
computational evidence supporting a deleterious effect on gene/
protein. Further studies are ongoing to find a possible correlation 
between the association of the two variants with the clinical phe-
notype, which was characterized by inflammatory bowel disease, 
susceptibility to viral infections, aspergillosis, T-cell lympho-
penia, and increased CD4 and CD8 double-negative T cells. 
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Alternatively, a second unidentified mutation of DOCK8 might 
account for the clinical manifestations of the patient. In patient 
011 with a T−B+NK− SCID phenotype associated with deafness, 
microcephaly, brain and cerebellar atrophy, developmental delay, 
NGS revealed 2 heterozygous mutations of ADA gene, located 
in the same allele, the first one being likely pathogenic, and a 
further heterozygous variant of unknown significance of ERCC6 
gene. The latter gene, which encodes for Cockayne syndrome B 
protein, has been recently described as essential for postnatal 
neuronal differentiation and neuritogenesis (38). Intriguingly, 
the patient showed also some neurological manifestations, 
such as macrocephaly and moderate grade cerebral atrophy. In 
patient 012 affected with hemophagocytic lymphohistiocytosis 
and marked reduction of perforin expression in NK cells, we 
identified two heterozygous mutations in PRF1 that were located 
in the same allele as shown by Sanger sequencing. In the same 
patient, we have also detected heterozygous variants in AP3B1 
and ADAMTS13 genes that have been implicated in NK activity 
as well.
The last group of patients included 10 patients with a complex 
disorder that was not typical of any known syndrome and was 
associated with multiple genetic variants, each of them was not 
per  se causative individually of that disorder (Table  4). In this 
group, it was not possible to draw any correlation between the 
genetic variations that were detected and the pathogenesis of 
the disorders. However, these alterations of unknown biologic 
significance were found in several genes implicated in immuno-
logical functions at different extent.
In the remaining 23 patients who were analyzed by NGS, 
including 9 studied by T-NGS and 15 by WES, we could not 
identify any candidate variants. These unsolved datasets will be 
re-analyzed when new bioinformatics tools become available and 
as new disease genes are described.
DiscUssiOn
The advent of NGS technologies has given the possibility to 
physicians to investigate multiple genes assay, to provide great 
opportunities for diagnosing patients affected with complex 
disorders of the immune system, and to increase our knowledge 
on the pathogenesis of these genetic disorders (39).
In this study, we used NGS technologies to identify potential 
disease-causing mutations in patients affected with clinical 
phenotypes highly suggestive of a PID, which were still not 
diagnosed after using traditional sequential Sanger sequencing 
procedures. Thanks to this novel diagnostic approach, we report 
that a definitive diagnosis of PID was achieved in a timely man-
ner in 7 out of the 45 subjects. In three patients, the diagnosis 
was achieved through T-NGS, while, in the other four patients, 
the diagnosis was reached by WES. In all these subjects, the 
application of a clear-cut filtering strategy, consisting of targeted 
sequencing, bioinformatics analysis, phenotype-based filter-
ing criteria, and confirmartory functional assays and Sanger 
sequencing, led to the identification of the underlying immune 
disorder (Figure  1). With this approach, eight of the overall 
group of variants resulted in potentially disease-causing muta-
tions, distributed over seven patients.
We have divided NGS results into four categories: (I) genetic 
alterations associated with a canonical PID phenotype, 
(II) diagnostic genotype in atypical presentation, (III) genetic 
variants potentially involved in the immunological features, 
and (IV) multiple genetic variants, each of them was not per se 
causative individually of the disorder, even though the sum of 
variations of the different genes could be proven in the future 
of some pathogenic significance, as either causative or modifier 
factor.
The first and second groups included patients whose candidate 
genotypes were congruent with the immunologic features sug-
gesting a causal relationship. Of note, exome sequencing allowed 
the identification of PLDN variants associated with a novel 
genetic cause of partial albinism and with PID (29). This study 
reported six patients who had undergone a diagnostic odyssey 
of 10–21 months driven by worldwide accepted protocols (40). 
Unfortunately, this candidate gene approach, although function-
ally driven, failed to yield a diagnosis. The diagnosis was finally 
made possible with NGS technology in a much more timely 
manner (2 months).
In the second category of patients, which included patients 
carrying genetic variants previously reported, but associated 
with novel features of previously established phenotypes, the 
molecular definition of the diagnosis contributed to expanding 
the overall knowledge of pathogenetic mechanisms underlying 
that specific disorder. In the patient with MYD88 deficiency, the 
atypical presentation was characterized by chronic yersiniosis 
resulting in terminal ileitis and recurrent neutropenia, in the 
absence of invasive pneumococcal disease, as is expected in 
this rare immunodeficiency. The atypical clinical presentation 
was responsible for the diagnostic delay. Moreover, Sanger 
sequencing of four candidate genes (STAT3, ELANE, RAG1, and 
RAG2) had given negative results (27). Homozygous mutations 
of DOCK8 and CLEC7A were already reported as genetic cause 
of two distinct PIDs, such as autosomal recessive Hyper IgE 
syndrome and of CMC, respectively, but never observed in a 
single patient. It is likely that these genetic variants affecting two 
distinct loci, and probably concurring to the clinical manifesta-
tions of the patient, could not be identified without the avail-
ability of NGS (31).
The cases highlighted herein contribute to the explanation of 
several phenotypes for very rare disorders. Such broadening of 
the phenotypic spectrum is a phenomenon shared with many 
other rare disorders, as atypical patients are identified through 
NGS. In the case of congenital immune disorders, at the begin-
ning only the most severe forms are described (41). Only after 
years from the initial description of the syndrome milder features 
of the disease are recognized or extra-immunological clinical 
signs identified.
In the third group, NGS sequencing revealed multiple het-
erozygous genetic variants in each subject, some of them poten-
tially involved in the immunological features. All the variants of 
this group are either single heterozygous or in cis, thus further 
studied are needed, including WES or microarray testing to try 
to find the second mutation or uncover mutation(s) in a separate 
gene that fully explain(s) the phenotype. In the patient 012, the 
PRF1 gene alteration was proven to have functional relevance, 
FigUre 1 | Flowchart of the filtering strategy. A schematic overview of the approach/clear-cut strategy used to filter variants identified through T-NGS or WES 
in order to identify potentially causative mutations.
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since perforin expression in NK cells was reduced. However, the 
patient was not placed in the group 1 since the two heterozygous 
PRF1 variations were in cis at the Sanger sequencing. Previously, 
our group has documented that this heterozygous variation may 
act as a susceptibility cofactor, which under certain circumstances 
may be associated with a functional alteration (42).
Finally, the fourth group included patients showing multiple 
genotypic alterations associated with complex phenotypes that 
could not fit into defined clinical phenotypes. In this group, no 
genotype–phenotype relationship was possible. However, since 
these cases are extremely rare, these data should likewise be 
collected in a database. The creation of such a database might 
improve the interpretation of NGS results in those cases currently 
interpreted as no causative of the disorder. The identification of 
different individuals with the same phenotype and mutations in 
the same array of genes would suggest that the sum of variations 
in different genes exerts a pathogenic role, either as causative or 
as modifier factor.
However, even though in our study in 7 out of the 45 patients, 
a diagnosis was achieved, it should be considered that in the 
majority of the patients, target NGS approach did not allow to 
identify the genetic basis of the disease. Several aspects should 
be considered to interpret this observation. The first limitation 
is the limited number of the genes included on our targeted 
NGS panel. Moreover, the sequencing techniques do not provide 
enough coverage for intronic, promoter, or regulator regions. To 
overcome these technical limitations, whole exome or genome 
sequencing might be better strategies to deeply investigate these 
cases as the second-line diagnostic tool (14). Moreover, all NGS 
techniques, due to the generation of short reads, show a low 
sensitivity to detect complex structural variations (deletions, 
insertions, and inversions), repeat sequences, or complex rear-
rangement (43).
Based on these considerations, the identification of genetic 
defects in patients with PIDs is still a major challenge, and the 
functional implication of the variation must be considered man-
datory to definitely prove the relationship between the genetic 
alteration and the related phenotype.
Despite the above mentioned limitations, NGS technology 
represents a cost-effective and rapid first-line genetic approach 
for the evaluation of complex cases of PIDs. The advantage of 
this technique is the simultaneous sequencing of a panel of genes, 
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perhaps leading to the rapid identification of a diagnosis that may 
not have been otherwise considered using the traditional pheno-
type-driven approach. Overall, in spite of a moderately higher 
cost, at moment WES could represent the first-line approach 
to initial PID management. The sequential investigation of 
several candidate genes is, by comparison, a very time- and cost-
consuming process. Prompt diagnosis shows an unquestioned 
clinical advantage, allowing initiation of appropriate and often 
life-saving treatment.
aUThOr cOnTriBUTiOns
VG, GG, EC, VL, RC, and AP identified the pts and performed the 
immunological and phenotypic characterization; IT, EF, and CS 
performed the NGS and WES exps; RDA, AP, and VL performed 
the functional exps and the molecular confirmation exps; RB and 
CP interpreted the results; VG and CP wrote the manuscript; and 
RB and CP directed the project.
FUnDing
This study was partially funded by “Associazione 
Immunodeficienze primitive.”
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2016.00466
reFerences
1. Al-Herz W, Bousfiha A, Casanova I, Chatila TA, Conley ME, Cunningham-
Rundles C, et  al. Primary immunodeficiency diseases: an update on the 
classification from the International Union of Immunological Societies Expert 
Committee for primary immunodeficiency. Front Immunol (2014) 5:162. 
doi:10.3389/fimmu.2014.00162 
2. Cirillo E, Giardino G, Gallo V, D’Assante R, Grasso F, Romano R, et  al. 
Severe combined immunodeficiency-an update. Ann N Y Acad Sci (2015) 
1356:90–106. doi:10.1111/nyas.12849 
3. Parvaneh N, Casanova JL, Notarangelo LD, Conley ME. Primary immunode-
ficiencies: a rapidly evolving story. J Allergy Clin Immunol (2013) 131:314–24. 
doi:10.1016/j.jaci.2012.11.051 
4. de Greef JC, Wang J, Balog J, den Dunnen JT, Frants RR, Straasheijm KR, et al. 
Mutations in ZBTB24 are associated with immunodeficiency, centromeric 
instability, and facial anomalies syndrome type 2. Am J Hum Genet (2011) 
88:796–804. doi:10.1016/j.ajhg.2011.04.018 
5. Ghosh S, Krux F, Binder V, Gombert M, Niehues T, Feyen O, et  al. Array-
based sequence capture and generation sequencing for the identification 
of primary immunodeficiencies. Scand J Immunol (2012) 75:350–4. 
doi:10.1111/j.1365-3083.2011.02658.x 
6. Maffucci P, Filion CA, Boisson B, Itan Y, Shang L, Casanova JL, et  al. 
Genetic diagnosis using whole exome sequencing in common variable 
immunodeficiency. Front Immunol (2016) 7:220. doi:10.3389/fimmu.2016. 
00220 
7. Moshous D, Martin E, Carpentier W, Lim A, Callebaut I, Canioni D, 
et  al. Whole-exome sequencing identifies Coronin-1A deficiency in 3 
siblings with immunodeficiency and EBV-associated B-cell lymphoprolifer-
ation. J Allergy Clin Immunol (2013) 131:1594–603. doi:10.1016/j.jaci.2013. 
01.042 
8. Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, 
et al. Establishing diagnostic criteria for severe combined immunodeficiency 
disease (SCID), leaky SCID, and Omenn syndrome: the primary immune 
deficiency treatment consortium experience. J Allergy Clin Immunol (2014) 
133:1092–8. doi:10.1016/j.jaci.2013.09.044 
9. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol (2010) 
125:S182–94. doi:10.1016/j.jaci.2009.07.053 
10. Van der Burg M, Gennery AR. Educational paper. The expanding clinical 
and immunological spectrum of severe combined immunodeficiency. Eur 
J Pediatr (2011) 170:561–71. doi:10.1007/s00431-011-1452-3 
11. Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, 
et al. The natural history of children with severe combined immunodeficiency: 
baseline features of the first fifty patients of the Primary Immune Deficiency 
Treatment Consortium prospective study 6901. J Clin Immunol (2013) 
33:1156–64. doi:10.1007/s10875-013-9917-y 
12. Markert ML, Marques J, Neven B, Devlin B, McCarthy E, Chinn I, et al. First 
use of thymus transplantation therapy for Foxn1 deficiency (nude/SCID): a 
report of two cases. Blood (2011) 117:688–96. doi:10.1182/blood-2010-06- 
292490 
13. Oliveira JB, Fleisher TA. Laboratory evaluation of primary immunodeficien-
cies. J Allergy Clin Immunol (2010) 125(2 Suppl 2):S297–305. doi:10.1016/j.
jaci.2009.08.043 
14. Chou J, Ohsumi TK, Geha RS. Use of whole exome and genome sequenc-
ing in the identification of genetic causes of primary immunodeficiency. 
Curr Opin Allergy Clin Immunol (2012) 12:623–8. doi:10.1097/ACI. 
0b013e3283588ca6 
15. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA, et al. 
Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev 
Genet (2011) 12:745–55. doi:10.1038/nrg3031 
16. Moens L, Falk-Sorqvist E, Asplund AC, Bernatowska E, Smith CI, Nilsson M. 
Diagnostics of primary immunodeficiency disease: a sequencing capture 
approach. PLoS One (2014) 9:e114901. doi:10.1371/journal.pone.0114901 
17. Nijman IJ, van Montfrans JM, Hoogstraat M, Boes ML, van de Corput L, 
Renner ED, et al. Target next-generation sequencing: a novel diagnostic tool 
for primary immunodeficiencies. J Allergy Clin Immunol (2014) 133:529–34. 
doi:10.1016/j.jaci.2013.08.032 
18. Stoddard JL, Niemela JE, Fleisher TA, Rosenzweig SD. Target NGS: a cost- 
effective approach to molecular diagnosis of PIDs. Front Immunol (2014) 
5:531. doi:10.3389/fimmu.2014.00531 
19. Mousallem T, Urban TJ, McSweeney KM, Kleinstein SE, Zhu M, Adeli M, 
et  al. Clinical application of whole-genome sequencing in patients with 
primary immunodeficiency. J Allergy Clin Immunol (2015) 136:476–9.e6. 
doi:10.1016/j.jaci.2015.02.040 
20. Aloj G, Giardino G, Valentino L, Maio F, Gallo V, Esposito T, et  al. Severe 
combined immunodeficiences: new and old scenarios. Int Rev Immunol 
(2012) 31:43–65. doi:10.3109/08830185.2011.644607 
21. Saunders CJ, Miller NA, Soden SE, Dinwiddie DL, Noll A, Alnadi NA, 
et  al. Rapid whole-genome sequencing for genetic disease diagnosis in 
neonatal intensive care units. Sci Transl Med (2012) 4:154ra135. doi:10.1126/
scitranslmed.3004041 
22. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards 
and guidelines for the interpretation of sequence variants: a joint consensus 
recommendation of the American College of Medical Genetics and Genomics 
and the Association for Molecular Pathology. Genet Med (2015) 17:405–24. 
doi:10.1038/gim.2015.30 
23. Kingsmore SF, Dinwiddie DL, Miller NA, Soden SE, Saunders SE, Saunders 
CJ. Adopting orphans: comprehensive genetic testing of Mendelian disease 
of childhood by next-generation sequencing. Exp Rev Mol Diagn (2011) 
11:855–68. doi:10.1586/erm.11.70 
24. Hernandez A, Berron-Ruiz L, Staines-Boone T, Zarate-Hernandez M, 
Cordova-Calderon WO, Espinosa-Rosales FJ, et  al. Clinical and genetic 
analysis of patients with X-linked hyper-IgM syndrome. Clin Genet (2013) 
83:585–7. doi:10.1111/j.1399-0004.2012.01953.x 
25. Holinski-Feder E, Weiss M, Brandau O, Jedele KB, Nore B, Bsckesjš CM, 
et  al. Mutation screening of the BTK gene in 56 families with X-linked 
agammaglobulinemia (XLA): 47 unique mutations without correla-
tion  to  clinical course. Pediatrics (1998) 101:276–84. doi:10.1542/peds.101. 
2.276 
10
Gallo et al. Next-Generation Sequencing in Primary Immunodeficiencies
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 466
26. Dotta L, Scomodon O, Padoan R, Timpano S, Plebani A, Soresina A, et al. 
Clinical heterogeneity of dominant chronic mucocutaneous candidiasis dis-
ease: presenting as treatment-resistant candidiasis and chronic lung disease. 
Clin Immunol (2016) 164:1–9. doi:10.1016/j.clim.2015.12.010 
27. Giardino G, Gallo V, Somma D, Farrow EG, Thiffault I, D’Assante R, et  al. 
Target next-generation sequencing revealed MYD88 deficiency in a child with 
chronic yersiniosis and granulomatous lymphadenitis. J Allergy Clin Immunol 
(2016) 137:1591–5. doi:10.1016/j.jaci.2015.09.050 
28. Yamamoto T, Tsutsumi N, Tochio H, Ohnishi H, Kubota K, Kato Z, et  al. 
Functional assessment of the mutational effect of human IRAK4 and 
MyD88 genes. Mol Immunol (2014) 58:66–66. doi:10.1016/j.molimm.2013. 
11.008 
29. Badolato R, Pradini A, Caracciolo S, Colombo F, Tabellini G, Giacomelli 
M, et  al. Exome sequencing reveals a pallidin mutation in a Hermansky-
Pudlak-like primary immunodeficiency syndrome. Blood (2012) 119:3185–7. 
doi:10.1182/blood-2012-01-404350 
30. Cullinane AR, Curry JA, Carmona-Rivera C, Summers CG, Ciccone C, 
Cardillo ND, et al. A BLOC-1 mutation screen reveals that PLDN is mutated 
in Hermansky-Pudlak syndrome type. Am J Hum Genet (2011) 88:778–87. 
doi:10.1016/j.ajhg.2011.05.009 
31. Dinwiddle DL, Kningsmore SF, Caracciolo S, Rossi G, Moratto D, Mazza C, 
et al. Combined DOCK8 and CLEC7A mutations causing immunodeficiency 
in 3 brothers with diarrhea, eczema, and infections. J Allergy Clin Immunol 
(2013) 131:594–7. doi:10.1016/j.jaci.2012.10.062 
32. Arico’ M, Boggio E, Cetica V, Melensi M, Orilieri E, Clemente N, et  al. 
Variations of the UNC13D gene in patients with autoimmune lymphopro-
liferative syndrome. PLoS One (2013) 8:e68045. doi:10.1371/journal.pone. 
0068045 
33. Arredondo-Vega FX, Santisteban I, Daniels S, Toutain S, Hershfield MS. 
Adenosine deaminase deficiency: genotype-phenotype correlations based on 
expressed activity of 29 mutant alleles. Am J Hum Genet (1998) 63:1049–59. 
doi:10.1086/302054 
34. Ozsahin H, Arredondo-Vega FX, Santisteban I, Fuhrer H, Tuchschmid P, 
Jochum W, et  al. Adenosine deaminase deficiency in adults. Blood (1997) 
89:2849–55. 
35. Feldmann J, Le Deist F, Ouachze-Chardin M, Certain S, Alexander S, 
Quartier P, et al. Functional consequences of perforin gene mutations in 22 
patients with familial heamophagocytic lymphohistiocytosis. Br J Haematol 
(2002) 117:965–72. doi:10.1046/j.1365-2141.2002.03534.x 
36. Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, 
MyD88, NEMO, or IkBa deficiency. Clin Microbiol Rev (2011) 24:490–7. 
doi:10.1128/CMR.00001-11 
37. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, et al. Pyogenic bac-
terial infections in humans with MyD88 deficiency. Science (2008) 321:691–6. 
doi:10.1126/science.1158298 
38. Ciaffardini F, Nicolai S, Caputo M, Canu G, Paccosi E, Costantino M, et al. 
The Cockayne syndrome B protein is essential for neuronal differentiation 
and neuritogenesis. Cell Death Dis (2014) 5:e1268. doi:10.1038/cddis. 
2014.228 
39. O’Connell AE, Volpi S, Dobbs K, Fiorini C, Tsitsikov E, de Boer H, et al. Next 
generation sequencing reveals skewing of the T and B cell receptor repertoires 
in patients with Wiskott-Aldrich syndrome. Front Immunol (2014) 5:340. 
doi:10.3389/fimmu.2014.00340 
40. De Vries E, Alvarez Cardona A, Abdul Latiff AH, Badolato R, Brodszki N, 
Cant AJ, et  al. Patient-centred screening for primary immunodeficiency, 
a multi-stage diagnostic protocol designed for non-immunologists: 2011 
update. Clin Exp Immunol (2012) 167:108–19. doi:10.1111/j.1365-2249.2011. 
04461.x 
41. Maggina P, Gennery AR. Classification of primary immunodeficiencies: 
need for a revised approach? J Allergy Clin Immunol (2013) 131:292–4. 
doi:10.1016/j.jaci.2012.10.008 
42. Busiello R, Adriani M, Locatelli F, Galgani M, Fimiani G, Clementi R, et al. 
Atypical features of familial hemophagocytic lymphohistiocytosis. Blood 
(2004) 103:4610–2. doi:10.1182/blood-2003-10-3551 
43. Clark MJ, Chen R, Lam HY, Karczewski KJ, Chen R, Euskirchen G, et  al. 
Performance comparison of exome DNA sequencing technologies. Nat 
Biotechnol (2011) 29:908–14. doi:10.1038/nbt.1975 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
The reviewer JN and handling editor declared their shared affiliation, and the 
handling editor states that the process nevertheless met the standards of a fair and 
objective review.
Copyright © 2016 Gallo, Dotta, Giardino, Cirillo, Lougaris, D’Assante, Prandini, 
Consolini, Farrow, Thiffault, Saunders, Leonardi, Plebani, Badolato and Pignata. 
This is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
